WallStreetZenWallStreetZen

NASDAQ: RDUS
Radius Recycling Stock

$21.13+0.48 (+2.32%)
Updated Mar 28, 2024
RDUS Price
$21.13
Fair Value Price
$19.24
Market Cap
$588.72M
52 Week Low
$17.51
52 Week High
$36.64
P/E
-22.97x
P/B
0.67x
P/S
0.25x
PEG
N/A
Dividend Yield
3.55%
Revenue
$2.96B
Earnings
-$25.97M
Gross Margin
10.1%
Operating Margin
-0.43%
Profit Margin
-0.9%
Debt to Equity
0.92
Operating Cash Flow
$200M
Beta
1.29
Next Earnings
Apr 4, 2024
Ex-Dividend
N/A
Next Dividend
N/A

RDUS Overview

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.

Zen Score

–
Industry Average (34)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RDUS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RDUS ($21.13) is overvalued by 9.84% relative to our estimate of its Fair Value price of $19.24 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RDUS ($21.13) is not significantly undervalued (9.84%) relative to our estimate of its Fair Value price of $19.24 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RDUS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more RDUS due diligence checks available for Premium users.

Be the first to know about important RDUS news, forecast changes, insider trades & much more!

RDUS News

Valuation

RDUS fair value

Fair Value of RDUS stock based on Discounted Cash Flow (DCF)
Price
$21.13
Fair Value
$19.24
Overvalued by
9.84%
RDUS ($21.13) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RDUS ($21.13) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RDUS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

RDUS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-22.97x
Industry
14.67x
Market
44.51x

RDUS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.67x
Industry
1.05x
RDUS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

RDUS's financial health

Profit margin

Revenue
$672.9M
Net Income
-$18.0M
Profit Margin
-2.7%
RDUS's Earnings (EBIT) of -$12.78M... subscribe to Premium to read more.
Interest Coverage Financials
RDUS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.7B
Liabilities
$808.4M
Debt to equity
0.92
RDUS's short-term assets ($535.45M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RDUS's short-term assets ($535.45M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RDUS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
RDUS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.3M
Investing
-$24.2M
Financing
$23.8M
RDUS's operating cash flow ($200.22M)... subscribe to Premium to read more.
Debt Coverage Financials

RDUS vs Steel Stocks

TickerMarket Cap1d %P/EP/B
RDUS$588.72M+2.32%-22.97x0.67x
ZEUS$789.07M+1.00%18.41x1.42x
ASTL$879.59M+0.71%21.44x0.82x
MSB$232.22M-0.11%20.58x10.99x
USAP$203.76M-8.94%-140.13x0.91x

Radius Recycling Stock FAQ

What is Radius Recycling's quote symbol?

(NASDAQ: RDUS) Radius Recycling trades on the NASDAQ under the ticker symbol RDUS. Radius Recycling stock quotes can also be displayed as NASDAQ: RDUS.

If you're new to stock investing, here's how to buy Radius Recycling stock.

What is the 52 week high and low for Radius Recycling (NASDAQ: RDUS)?

(NASDAQ: RDUS) Radius Recycling's 52-week high was $36.64, and its 52-week low was $17.51. It is currently -42.33% from its 52-week high and 20.67% from its 52-week low.

How much is Radius Recycling stock worth today?

(NASDAQ: RDUS) Radius Recycling currently has 27,861,685 outstanding shares. With Radius Recycling stock trading at $21.13 per share, the total value of Radius Recycling stock (market capitalization) is $588.72M.

Radius Recycling stock was originally listed at a price of $9.35 in Dec 31, 1997. If you had invested in Radius Recycling stock at $9.35, your return over the last 26 years would have been 125.92%, for an annualized return of 3.18% (not including any dividends or dividend reinvestments).

How much is Radius Recycling's stock price per share?

(NASDAQ: RDUS) Radius Recycling stock price per share is $21.13 today (as of Mar 28, 2024).

What is Radius Recycling's Market Cap?

(NASDAQ: RDUS) Radius Recycling's market cap is $588.72M, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Radius Recycling's market cap is calculated by multiplying RDUS's current stock price of $21.13 by RDUS's total outstanding shares of 27,861,685.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.